Bone DensityPhase 3NCT00784940
ATAC - Bone Density Sub-Protocol
A Phase 3 study testing Anastrozole and Tamoxifen in people with Bone Density, run by AstraZeneca.
Trial summary
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy. Read more about this study
- Who is it for?
- Ages 45 years and older, women only
- Conditions the study is for
- Bone Density
- What is being tested?
- Anastrozole and Tamoxifen
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 308 participants
- Where
- No sites listed yet
- Study dates
- Jun 1998to Apr 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Eligible for entry into the main ATAC trial 1033IL/0029
- Women defined as post-menopausal
- Patients with histologically proven operable invasive breast cancer
- Who following primary surgery have a good prognosis and would be ethically suitable to remain untreated
Who cannot join
- Excluded from entry into the main ATAC trial (1033IL/0029)
- Patients who have received hormone replacement therapy within the previous 12 months prior to randomisation
- Patients who have received bisphosphonate therapy within the previous 12 months prior to randomisation
- Patients who have had a bone fracture within the previous 6 months prior to randomisation
About this study
Official title: A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.
- Conditions
- Bone Density
- Being tested
- Anastrozole, Tamoxifen
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AnastrozoleDrug
Also called Arimidex
1mg, orally, once daily
TamoxifenDrug
Also called Nolvadex
20mg, orally, once daily
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Arimidex 1mg + Nolvadex placebo Receives: Drug: Anastrozole |
| 2 | Active comparator | Arimidex placebo + Nolvadex 20mg Receives: Drug: Anastrozole; Drug: Tamoxifen |
| 3 | Active comparator | Arimidex 1mg + Nolvadex 20mg Receives: Drug: Tamoxifen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to withdrawal
Time to recurrence
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2008 (estimated)
- Study startJun 1998
- Primary completionMar 2005
- Study completionApr 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bone DensityStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 308 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00784940
- Sponsor's protocol ID
- 1033ID/0029
- Other IDs
- D5392C01985
- Status last verified
- Apr 2009
- First submitted
- 3 Nov 2008
- Last updated
- 27 Apr 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
- ClinicalTrials.gov ID
- NCT00784940
- Acronym / sponsor ID
- 1033ID/0029
- Conditions
- Bone Density
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 308 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Jun 1998
- Primary completion
- Mar 2005 (actual)
- Study completion
- Apr 2007 (actual)
- First posted
- 4 Nov 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: AnastrozoleArimidex 1mg + Nolvadex placebo |
| 2 | Active comparator | Drug: Anastrozole, Drug: TamoxifenArimidex placebo + Nolvadex 20mg |
| 3 | Active comparator | Drug: TamoxifenArimidex 1mg + Nolvadex 20mg |
Who may qualify
- Ages
- 45 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Eligible for entry into the main ATAC trial 1033IL/0029
- Women defined as post-menopausal
- Patients with histologically proven operable invasive breast cancer
- Who following primary surgery have a good prognosis and would be ethically suitable to remain untreated
Key exclusion criteria (4 listed)
- Excluded from entry into the main ATAC trial (1033IL/0029)
- Patients who have received hormone replacement therapy within the previous 12 months prior to randomisation
- Patients who have received bisphosphonate therapy within the previous 12 months prior to randomisation
- Patients who have had a bone fracture within the previous 6 months prior to randomisation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AnastrozoleAlso: Arimidex1mg, orally, once daily | Drug | 1, 2 |
| TamoxifenAlso: Nolvadex20mg, orally, once daily | Drug | 2, 3 |
Primary outcome
Time to withdrawal
Time to recurrence
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2009.
Related trials for Bone Density
Recruiting
Digital Eye®-Assisted Bone Density Classification and Primary Dental Implant Stability.
Bone Mineral Density, Primary Implant Stability
RecruitingObservational study
Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density
Acute Lymphoblastic Leukemia
Not yet recruitingObservational study
Comparing Lumbar Fusion With and Without Stress Endplate Augmentation in Patients With Low Bone Mass
Degenerative Lumbar Disease
RecruitingPhase 4
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Mild Autonomous Cortisol Secretion (MACS)
Not yet recruiting
DEXA Bone Density Analysis of the CoreHip® Prosthesis System
Primary Osteoarthritis, Cartilage Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Anastrozole and Tamoxifen in people with Bone Density, run by AstraZeneca.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Apr 2009. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to withdrawal. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2009.